Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

Unlike traditional insulin therapies, GLP-1 RAs enhance insulin secretion only when blood glucose levels are elevated, reducing the risk of hypoglycemia. By acting on the central nervous system, GLP-1 ...

GLP-1s improve different mechanisms involved in insulin resistance, including delaying gastric emptying (which slows down ...

Five researchers have been jointly awarded one of this year's Breakthrough Prizes in Life Sciences for their contributions to ...

GLP-1 agonists may lead to increased nausea and vomiting in the early postoperative period after total hip arthroplasty, ...

Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, ...

The market for GLP-1 medication is estimated by several forecasters to bring in over $100 billion in annual revenue within the next decade. But the drug category, initially developed for diabetes but ...